started · updated
GLP-1 receptor agonists linked to lower colorectal cancer risk
A systematic review and meta-analysis of 17 studies involving 36,415 patients has identified an association between GLP-1 receptor agonists and a reduced risk of colorectal cancer in adults with type 2 diabetes or obesity. The research, conducted by scientists in China, suggests these medications—commonly used for blood sugar control and weight management—may offer protective benefits against specific types of colon cancer.
However, the study noted no significant impact on the risk of general intestinal cancer or rectal cancer. While the drugs are effective for metabolic health, patient reports highlight various side effects. In community discussions, women have reported gastrointestinal issues, changes in taste and alcohol tolerance, and potential iron deficiencies, emphasizing that individual experiences with dosage and comorbidities vary significantly.